Form 4: Lyell Immunopharma Director Robert Nelsen Reports Acquisition of Options

Director Robert Nelsen reports acquisition of options and indirect ownership of common stock through ARCH Venture Funds.

Summary

• Robert Nelsen, a director at Lyell Immunopharma, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• The report indicates the acquisition of 130,000 options with an exercise price of $2.36, vesting on the earlier of the next annual meeting or the first anniversary of June 14, 2024, expiring on June 13, 2034.
• Nelsen also indirectly owns 18,206,358 shares of common stock through ARCH Venture Fund IX, L.P. and ARCH Venture Fund IX Overage, L.P.
• Nelsen disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating changes in ownership. The acquisition of options could be seen as a slightly positive signal, but it's not a major event.

Positives

• The acquisition of options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in Robert Nelsen's holdings in Lyell Immunopharma.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.

Key Dates